母永超,王小飞,蔡林

• 1:天津中医药大学
• 2:天津第一中心医院国际医疗中心

摘要(Abstract)：

目的比较服用替格瑞洛与氯吡格雷后血浆中的腺苷浓度,并分析其对发生不良临床事件的影响。方法入选2014年6月至2016年7月在天津第一中心医院国际医疗中心住院的180例经皮冠状动脉介入治疗术后患者,根据数字随机表法分为观察组(90例),给予替格瑞洛90 mg、每日2次;对照组(90例),给予氯吡格雷75 mg、每日1次。分别比较两组患者术后30 d、90 d时血浆中腺苷的浓度,观察分析相关临床效应。结果观察组患者术后30 d腺苷浓度[(1.65±0.16)μmol/L比(0.71±0.08)μmol/L,P<0.001]、90 d腺苷浓度[(1.65±0.14)μmol/L比(0.72±0.06)μmol/L,P<0.001]均显著高于对照组,差异均有统计学意义。观察组患者术后30 d(3.3%比13.3%,P<0.05)、90 d(6.7%比15.6%,P<0.05)时主要不良心脑血管事件发生率均显著大于对照组,差异均有统计学意义;两组患者术后30 d、90 d出血事件发生率比较,差异均无统计学意义(均P>0.05)。结论服用替格瑞洛可明显增加血浆中腺苷的浓度,同时可减少不良事件发生率,具有良好的临床效应。

关键词(KeyWords)： 替格瑞洛;氯吡格雷;经皮冠状动脉介入治疗;腺苷

Abstract:

Keywords:

基金项目(Foundation): 天津市卫生局科技基金(2015KZ037)

作者(Author): 母永超,王小飞,蔡林

参考文献(References)：

• [1]古航宇.冠心病患者冠状动脉病变严重程度与冠心病危险因素的相关分析.中西医结合心血管病电子杂志,2015,3(34):3-4.
• [2]韩雅玲.《2016年美国心脏病学/美国心脏协会冠心病患者双联抗血小板治疗疗程指南更新》解读.中国介入心脏病学杂志,2016,24(11):603-606.
• [3]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [4]Springthorpe B,Bailey A,Barton P,et al.From ATP to AZD6140:the discovery of an orally active reversible P2Y12receptor antagonist for the prevention of thrombosis.Bioorg Med Chem Lett,2007,17(21):6013-6018.
• [5]Headrick JP,Lasley RD.Adenosine receptors and reperfusion injury of the heart.Handb Exp Pharmacol,2009,(193):189-214.
• [6]杨影红,孙鑫,田野.替格瑞洛增强腺苷生物学效应的研究进展.临床心血管病杂志,2015,31(2):122-124.
• [7]李蕙君,李占全,张明,等.急性心肌梗死溶栓再通临床标准与冠状动脉造影的对比研究.中国实用内科杂志,2000,20(11):686-687.
• [8]Tamis-Holland JE,O'Gara P.Highlights from the 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction and beyond.Clin Cardiol,2014,37(4):252-259.
• [9]Storey RF,Husted S,Harrington RA,et al.Inhibition of platelet aggregation by AZD6140,A Reversible Oral P2Y 12,receptor antagonist,compared with clopidogrel in patients with acute coronary syndromes.J Am Coll Cardiol,2007,50(19):1852-1856.
• [10]Bonello L,Laine M,Kipson N,et al.Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.J Am Coll Cardiol,2014,63(9):872-877.
• [11]Wang K,Zhou X,Huang Y,et al.Adjunctive treatment with ticagrelor,but not clopidogrel,added to t PA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.Thromb Haemost,2015,104(3):609-617.
• [12]Wittfeldt A,Emanuelsson H,Brandrup-Wognsen G,et al.Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.J Am Coll Cardiol,2013,61(7):723-727.
• [13]Landauer TK,Dumais ST.A solution to plato's problem:The latent semantic analysis theory of acquisition,induction,and representation of knowledge.Psychological Review,1997,104(2):211-240.
• [14]Robinson JG,Stone NJ.The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk:a new paradigm supported by more evidence.Eur Heart J,2015,36(31):2110-2118.
• [15]高润霖.替格瑞洛——ACS患者的更好选择.医学研究杂志,2011,40(1):1-2.
• [16]陈刚.替格瑞洛在急性冠状动脉综合征治疗中的研究进展.中外医疗,2015,34(24):196-198.
• [17]张萌萌.陈旧性心梗患者长期使用替格瑞洛可获益.临床药物治疗杂志,2016,14(1):86-86.
• [18]张士庆,朱永宏.替格瑞洛引起血尿酸升高机制及治疗策略.中国循证心血管医学杂志,2016,8(4):511-512.
• [19]张士庆,朱永宏.替格瑞洛引起肌酐升高机制的研究进展.中国循环杂志,2016,31(7):718719.
• [20]Hong JL,Ho CY,Kwong K,et al.Activation of pulmonary C fibres by adenosine in anaesthetized rats:role of adenosine A1receptors.J Physiol,1998,508(Pt 1):109-118.
• [21]Scirica BM,Cannon CP,Emanuelsson H,et al.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(Platelet Inhibition and Patient Outcomes)trial:results of the continuous electrocar—diographic assessment substudy.J Am Coll Cardiol,2011,57(19):1908-1916.